SOURCE: Leerink Swann & Company

July 12, 2005 07:10 ET

Leerink Swann & Company Initiates Coverage of CoTherix, Inc. (NASDAQ: CTRX)

BOSTON, MA -- (MARKET WIRE) -- July 12, 2005 -- Yesterday after the close, Senior Biotechnology Analyst, Andrew Fein, initiated coverage of CoTherix, Inc. with an Outperform rating. Mr. Fein's investment rating is based on a proprietary MEDACorp survey which suggests that the market underestimates the sales potential for CoTherix's lead product, Ventavis, and his belief that CoTherix's next-generation battery-operated, portable nebulizer should help drive usage next year.

About CoTherix, Inc.

CoTherix, Inc. (NASDAQ: CTRX) is a biopharmaceutical company focused on licensing, developing, and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix is headquartered in South San Francisco, California.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564
    www.leerink.com